title: Will doxorubicin-containing regimens replace MOPP and its variants?
authors.affiliation: Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts.
authors.forename: G P
authors.initials: GP
authors.lastname: Canellos
authors.forename: W
authors.initials: W
authors.lastname: Rosenberg
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage*; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008466:Mechlorethamine / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D011446:Prospective Studies; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D004317:Doxorubicin; D011241:Prednisone